Trials / Completed
CompletedNCT01647516
Efficacy and Safety Study of Ozanimod in Ulcerative Colitis
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo Controlled Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of Induction Therapy With RPC1063 in Patients With Moderately to Severely Active Ulcerative Colitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 199 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years – 73 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether RPC1063 is effective in the treatment of ulcerative colitis (UC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ozanimod | Ozanimod capsules by mouth daily. |
| DRUG | Placebo |
Timeline
- Start date
- 2012-12-26
- Primary completion
- 2015-03-10
- Completion
- 2019-08-30
- First posted
- 2012-07-23
- Last updated
- 2021-05-19
- Results posted
- 2020-10-14
Locations
88 sites across 15 countries: United States, Australia, Belgium, Bulgaria, Canada, Greece, Hungary, Israel, Netherlands, New Zealand, Poland, Russia, Slovakia, South Korea, Ukraine
Source: ClinicalTrials.gov record NCT01647516. Inclusion in this directory is not an endorsement.